Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2022 · 10-Q
Revenue$123.55M$123.55M+49.0% vs Q2 2021 Net Income-$5.19M-$5.19MN/M vs Q2 2021 EPS Diluted-$0.15-$0.15N/M vs Q2 2021 Gross Profit$52,364,000+4.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$40,451,000+37.0% Free Cash Flowderived$39,990,000+38.8% Margins · derivedGross margin42.4%−18.2 pt vs Q2 2021
Operating margin9.0%−10.8 pt vs Q2 2021
Net margin-4.2%−92.0 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end